Ionis-Otsuka offer 'groundbreaking' improvement in function and survival for genetic type of ALS
Phase 3positiveUlefnersenPositive
AI Analysis
Summary
Ionis Pharmaceuticals and Otsuka Pharmaceutical announced positive Phase 3 trial results for Ulefnersen, an RNA-targeted therapy for rare genetic ALS, showing improvements in functional impairment and survival. The companies plan to seek FDA approval based on these results.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Improved measurements of functional impairment and survival in patients with rare genetic ALS subtype
Importance:8/10
Sentiment:
0.85
ALSRare diseaseRNA-targeted therapyPhase 3 positiveGenetic diseaseFDA approval pathway
Read the original article
Published by BioSpace on September 23, 2026 12:43 PM